Announcements and Notices - [Announcement by Offeror Company under the Takeovers Code / Announcement by Offeree Company under the Takeovers Code / Group Restructuring or Scheme of Arrangement / Privatisation/Withdrawal or Cancellation of Listing of Securities / Inside Information]

YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs.  The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.

Joint Announcement
Fulfilment Of A Pre-Condition Of
The Proposed Pre-Conditional Privatisation Of
Yichang Hec Changjiang Pharmaceutical Co., Ltd.
By Sunshine Lake Pharma Co., Ltd. By Way Of
Merger By Absorption Of
Yichang Hec Changjiang Pharmaceutical Co., Ltd.
And
Update On The Listing Of Offeror H Shares

Announcements and Notices - [Announcement by Offeror Company under the Takeovers Code / Announcement by Offeree Company under the Takeovers Code]

Joint Announcement
Monthly Update
In Relation To The Proposed Pre-Conditional Privatisation
Of Yichang Hec Changjiang Pharmaceutical Co., Ltd.
By Sunshine Lake Pharma Co., Ltd.
By Way Of Merger By Absorption Of
Yichang Hec Changjiang Pharmaceutical Co., Ltd.

Sunshine Lake Pharma Co., Ltd. And
Yichang Hec Changjiang Pharmaceutical Co., Ltd.
To Enter Into A Licensing Agreement With
Shenyang Sunshine Pharmaceutical., Ltd.
To Commercialise Clifutinib Besylate

Sunshine Lake Pharma Co., Ltd. To Enter Into A Licensing Agreement With Apollo To Develop And Commercialise Apl-18881 (Hec88473) , A Fgf21 / Glp-1 Dual Receptor Agonist

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Joint Announcement Monthly Update In Relation To The Proposed Pre-Conditional Privatisation Of Yichang Hec Changjiang Pharmaceutical Co., Ltd. By Sunshine Lake Pharma Co., Ltd. By Way Of Merger By Absorption Of Yichang Hec Changjiang Pharmaceutical Co., Ltd.

Sunshine Lake Pharma Co., Ltd. And Yichang Hec Changjiang Pharmaceutical Co., Ltd. To Enter Into A Licensing Agreement With Shenyang Sunshine Pharmaceutical., Ltd. To Commercialise Clifutinib Besylate

Sunshine Lake Pharma Co., Ltd. To Enter Into A Licensing Agreement With Apollo To Develop And Commercialise Apl-18881 (Hec88473) , A Fgf21 / Glp-1 Dual Receptor Agonist

Joint Announcement Monthly Update In Relation To The Proposed Pre-Conditional Privatisation Of Yichang Hec Changjiang Pharmaceutical Co., Ltd. By Sunshine Lake Pharma Co., Ltd. By Way Of Merger By Absorption Of Yichang Hec Changjiang Pharmaceutical Co., Ltd.